Compare Enbridge Inc (ENB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Tango Therapeutics Inc. — how do they compare? Enbridge Inc trades at $47.52 (market cap $105.42B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Enbridge Inc is far larger — about 28.1× Tango Therapeutics Inc.'s market cap, and Enbridge Inc pays a 5.9% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 92 Days and Tango Therapeutics Inc. for 0 Days on average.
| ENB | TNGX | |
|---|---|---|
Market Cap | $105.42B | $3.75B |
Volume | 3,621,007 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $58.04 | $32.90 |
52-Week Low | $45.23 | $7.50 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $187.30B | $2.77B |
Dividend Yield | 5.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $47.35, up 0.85% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with three consecutive quarterly earnings beats and a 6% dividend yield. Revenue grew to $65.19 billion in 2025 with net income of $7.49 billion, though 2026 projections show margin compression. Recent news highlights ENB's expansion into European renewables and Permian Basin acquisitions as growth drivers.
ENB offers income investors a stable 6% yield with growth potential from its $41 billion project backlog, but faces headwinds from rising interest rates and potential oil price volatility. Analyst consensus is balanced with 48% buy ratings and a $61.63 price target suggesting 30% upside, though technical indicators remain cautious near-term.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
